Trials / Completed
CompletedNCT02604017
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 703 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to evaluate the efficacy and safety of ABT-493/ABT-530 in participants with Genotype 1 hepatitis C virus infection without cirrhosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-493/ABT-530 | Tablet; ABT-493 coformulated with ABT-530 |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2015-11-13
- Last updated
- 2021-07-13
- Results posted
- 2017-09-14
Source: ClinicalTrials.gov record NCT02604017. Inclusion in this directory is not an endorsement.